13d
Hosted on MSNSAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock UpSage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does ...
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder ...
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
Sage Therapeutics, Inc. (NASDAQ:SAGE) recently received an unsolicited bid proposal from Biogen Inc. (BIIB) to be purchased at around $7.22 per share. This represents a 30% premium to the price of ...
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results